BTMD compared with DFTX: revenue, margins and what each company keeps, and the suppliers and customers both name

BTMDbiote Corp.

Mkt capRevenueRevenue

DFTXDefinium Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

BTMDbiote Corp.

DFTXDefinium Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BTMD

Reportimpliedrealized× implied

Nov 5 '26—▼−15.45%—

Q2 FY26—▼−27.88%—

May 7 '26—▼−5.00%—

Q1 FY26—▼−10.47%—

DFTX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.9%0.00%×0.00

May 8 '26±9.7%▼−4.96%×0.52

= impliedBTMD realized, solidDFTX realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.9%

▲+0.93%

×0.07

Jan 12 '26—▲+0.29%—

BTMDbiote Corp.

1.04▼−15.28%· post 1.04

Mkt cap$44.2MRevenue$44MQ2 FY26Revenue$192MFY25

DFTXDefinium Therapeutics, Inc.

30.34▼−7.21%· post 30.39

ClosedNov 5 '26

Mkt cap$4.4BRevenue—Revenue—

Compare

ClosedNov 5 '26

BTMDbiote Corp.

DFTXDefinium Therapeutics, Inc.

1.04▼−15.28%post 1.04

Price

30.34▼−7.21%post 30.39

$44.2M

Mkt cap

$4.4B

Q2 FY26$44M

Revenue

—

FY25$192M

Revenue

—

BTMD1.04▼−15.28%vsDFTX30.34▼−7.21%ClosedNov 5 '26